Preparation method and use of liquid embolism agent having drug loading and developing functions

A technology of liquid embolizing agent and solvent, applied in application, medical science, surgical adhesive, etc., can solve the problems such as the inability to accurately observe the specific position of the microspheres, the separation of the microspheres and the contrast agent, and the high price of imported microspheres. , to achieve stable and reliable embolization effect, no cytotoxicity, and accurate embolization site.

Inactive Publication Date: 2018-04-13
杭州华微医疗科技有限公司
View PDF6 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These microspheres can embolize in the blood vessels for a long time without being degraded by the human body, so they will stay in the patient's body forever, forming a permanent embolism; moreover, the development and administration of most microspheres are carried out separately, that is to say, after separate After the microspheres and contrast agent are injected into the patient's body, the separation and disjoint of the microspheres and contrast agent may occur, so that the specific position of the microspheres cannot be accurately observed
Simply put, so far there is still no microsphere with its own developing performance.
In addition, imported microspheres are expensive and unbearable for patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method and use of liquid embolism agent having drug loading and developing functions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] 5g EVOH polymer was dissolved with 30mL N-methylpyrrolidone under heating and stirring. The sulfonating agent used was 5g concentrated sulfuric acid, and a little about 0.01g silver sulfate was added as a catalyst to accelerate the reaction. After heating and stirring at 70°C for 3 hours, it was cooled at room temperature. Pour the cooled copolymer into 200ml-300mL methanol to precipitate out, take the precipitate and add 25ml of N-methylpyrrolidone to dissolve it again, add 200ml-300mL methanol to make it precipitate again, repeat this several times, and finally remove the precipitate dry. Or use vacuum drying. The best obtained sulfonated modified EVOH copolymer, N-methylpyrrolidone, and Ta powder developer solution are mixed in a certain proportion, stirred and dissolved to obtain the liquid embolic agent HW01 of the present invention.

Embodiment 2

[0017] 5g EVOH polymer was dissolved with 30mL N-methylpyrrolidone under heating and stirring. The sulfonating agent used was 2.5g concentrated sulfuric acid, and a little about 0.01g silver sulfate was added as a catalyst to accelerate the reaction. After heating and stirring at 70°C for 3 hours, it was cooled at room temperature. Pour the cooled copolymer into 200ml-300mL methanol to precipitate out, take the precipitate and add 25ml of N-methylpyrrolidone to dissolve it again, add 200ml-300mL methanol to make it precipitate again, repeat this several times, and finally remove the precipitate dry. Or use vacuum drying. The best obtained sulfonated modified EVOH copolymer, N-methylpyrrolidone, and Ta powder developer solution are mixed in a certain proportion, stirred and dissolved to obtain the liquid embolic agent HW02 of the present invention. (The amount of sulfonation is halved compared with HW01)

Embodiment 3

[0019] 5g EVOH polymer was dissolved with 30mL N-methylpyrrolidone under heating and stirring. The sulfonating agent used was 5g chlorosulfonic acid, and a little about 0.01g silver sulfate was added as a catalyst to accelerate the reaction. After heating and stirring at 70°C for 2 hours, it was cooled at room temperature. Pour the cooled copolymer into 200ml-300mL methanol to precipitate out, take the precipitate and add 25ml of N-methylpyrrolidone to dissolve it again, add 200ml-300mL methanol to make it precipitate again, repeat this several times, and finally remove the precipitate dry. Or use vacuum drying. The best obtained sulfonated modified EVOH copolymer, N-methylpyrrolidone, and Ta powder developer solution are mixed in a certain proportion, stirred and dissolved to obtain the liquid embolic agent HW03 of the present invention.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a preparation method and a use of a liquid embolism agent having drug loading and developing functions. The liquid embolism agent is formed through mixing anion-modified polyethylene-polyvinyl alcohol copolymer (EVOH), a solvent and a developer according to a certain ratio. Negative ion groups are introduced to the high molecular chain of the EVOH through a chemical modification or grafting modification technology, and the negative ion groups can adsorb and load cationized chemotherapeutic anticancer drugs through positive and negative charge interactions. The solvent can be dimethyl sulfoxide (DMSO), N-methylpyrrolidone (NMP) or ethanol or a mixture of the DMSO, NMP and ethanol. The developer is a metallic tantalum micro-powder or an iodine-containing contrast agent or a mixture of the metallic tantalum micro-powder and the iodine-containing contrast agent. The liquid embolism agent can be widely applied to interventional embolization therapy, and is especiallysuitable for transcatheter arterial chemoembolization (TACE) therapy of liver cancer.

Description

Technical field [0001] The invention belongs to the field of TACE, Trans Arterial Chemo Embolization (Trans Arterial Chemo Embolization), and specifically relates to a preparation method and application of a liquid embolization agent capable of carrying medicine and having both visual properties. Background technique [0002] TACE, Trans Arterial Chemo Embolization (Trans Arterial Chemo Embolization) was first proposed by Japanese scholar Yamada in 1997. It was first used in the treatment of liver cancer, and now it has become the mainstream treatment option that more than 90% of patients with liver cancer in the middle and late stages will choose. It refers to the targeted infusion of embolic agents into the tumor focus through the femoral artery, abdominal aorta, and hepatic aorta under X-rays. The embolic agent embolizes and blocks the blood supply artery of the tumor. After the blood supply of the tumor tissue is blocked, the tumor cannot get the necessary nutrients for grow...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L24/04A61L24/00
CPCA61L24/00A61L24/001A61L24/0015A61L24/046A61L2300/416A61L2300/602C08L29/04
Inventor 徐平
Owner 杭州华微医疗科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap